Business Wire

CA-ENERGOUS

26.2.2020 22:04:06 CET | Business Wire | Press release

Share
Energous Secures Industry-first Regulatory Approval for its Revolutionary WattUp Wireless Charging Technology in Japan

Today Energous Corporation (Nasdaq: WATT), the developer of WattUp®, a revolutionary wireless charging 2.0 technology, announced that it has received regulatory approval for its WattUp Near Field wireless charging technology in Japan.

“Having secured regulatory approval for our WattUp wireless charging technology in Japan is a major regulatory milestone for Energous,” said Stephen R. Rizzone, president and CEO of Energous Corporation. “This opens the door to sell WattUp-enabled products in a major Asia Pacific market.”

Energous’ WattUp wireless charging technology underwent testing by independent, accredited test labs and was determined to be compliant with all regulatory requirements in Japan.

“WattUp approval in Japan is a big step forward for Energous and our customers, while increasing momentum to achieve global market access,” said Dan Lawless, vice president of regulatory affairs at Energous Corporation. “We are establishing a regulatory framework for the large-scale deployment of wireless charging 2.0 through our substantial engagements in major international spectrum and standards organizations, combined with our direct work with governments around the world.”

“Currently wireless charging technologies – specifically non coil-based charging solutions – have not yet penetrated the Japan market, largely because Japan has historically proven to have a more rigid regulatory approval process. Energous Corporation is paving the way for the industry in the Japan market with the industry-first approval of its WattUp wireless charging technology. With this breakthrough, Energous continues to show progress in advancing its WattUp technology to meet the needs of partner and customer companies,” said Dinesh Kithany, lead industry analyst, wireless power and power supply at Omdia.

Some of the benefits of Energous’ WattUp technology for manufacturers include:

  • A small footprint allowing WattUp to be integrated into products of various form factors, including small devices with curved edges or without flat surfaces
  • Orientation freedom and 90-degree angle support
  • Foreign object detection eliminating thermal issues with metal and other materials
  • Interoperability with all WattUp-enabled products, even those from different manufacturers

To-date, Energous has secured regulatory approval for its WattUp wireless charging technology in the following countries:

Afghanistan

Bermuda

Curacao

Germany

Kosovo

Netherlands

Suriname

Albania

Bolivia

Cyprus

Ghana

Latvia

New Zealand

Sweden

Andorra

Bosnia and Herzegovina

Czech Republic

Greece

Liechtenstein

Nicaragua

Switzerland

Angola

Botswana

Denmark

Grenada

Lithuania

Norway

Taiwan

Antigua and Barbuda

Brazil

Djibouti

Guatemala

Luxembourg

Panama

Tajikistan

Argentina

Brunei

Dominican Republic

Guyana

Macedonia

Peru

Tanzania

Armenia

Bulgaria

Dominica

Honduras

Malawi

Philippines

Thailand

Aruba

Burkina Faso

Ecuador

Hungary

Maldives

Poland

Trinidad and Tobago

Australia

Cambodia

Egypt

Iceland

Malta

Portugal

Turkey

Austria

Canada

El Salvador

India

Mexico

Romania

United Arab Emirates

Azerbaijan

Cayman Island

Eritrea

Indonesia

Monaco

Serbia

Uganda

Bahamas

Central African Republic

Estonia

Ireland

Mongolia

Slovenia

The United Kingdom

Barbados

Chile

Ethiopia

Italy

Montenegro

Solomon Island

The United States

Belarus

Colombia

Finland

Jamaica

Mozambique

Slovakia

Uruguay

Belgium

Costa Rica

France

Japan

Myanmar (formerly Burma)

South Africa

Uzbekistan

Belize

Croatia

Georgia

Jordan

Nepal

Spain

Venezuela

Energous anticipates it will receive regulatory approval in additional markets later this year.

To learn more about Energous, please visit Energous.com or follow the company on Twitter , Facebook and LinkedIn .

About Energous Corporation

Energous Corporation (Nasdaq: WATT) is leading the next generation of wireless charging – wireless charging 2.0 – with its award-winning WattUp® technology, which supports fast, efficient contact-based charging, as well as charging at a distance. WattUp is a scalable, RF-based wireless charging technology that offers substantial improvements in contact-based charging efficiency, foreign object detection, orientation freedom and thermal performance compared to older, coil-based charging technologies. The technology can be designed into many different sized electronic devices for the home and office, as well as the medical, industrial, retail and automotive industries, and it ensures interoperability across products. Energous develops silicon-based wireless power transfer (WPT) technologies and customizable reference designs. These include innovative silicon chips, antennas and software, for a large variety of applications, such as smartphones, fitness trackers, hearables, medical sensors and more. Energous received the world’s first FCC Part 18 certification for at-a-distance wireless charging, and the company has 220 awarded patents for its WattUp wireless charging technology to-date. For more information, please visit Energous.com .

Safe Harbor Statement

This press release contains forward-looking statements that describe our future plans and expectations. These statements generally use terms such as “believe,” “expect,” “may,” “will,” “should,” “could,” “seek,” “intend,” “plan,” “estimate,” “anticipate” or similar terms. Examples of our forward-looking statements in this release include our statements about technology developments, partner product development and wireless charging innovation. Our forward-looking statements speak only as of this date; they are based on current expectations and we undertake no duty to update them. Factors that could cause actual results to differ from what we expect include: uncertain timing of necessary regulatory approvals; timing of customer product development and market success of customer products; our dependence on distribution partners; and intense industry competition. We urge you to consider those factors, and the other risks and uncertainties described in our most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q, in evaluating our forward-looking statements.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 10:15:00 CEST | Press release

Doubtless combines industry-leading pet insurance with innovative care solutions, protecting more than 6 million pets across 10 global markets Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easie

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 09:19:00 CEST | Press release

Phase 1 study demonstrated pharmacokinetic (PK) equivalence between SB27 and Keytruda; Phase 3 study demonstrated equivalent objective response rate (ORR) at Week 24Phase 1 and Phase 3 studies expected to be completed within 2026 Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patie

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 09:00:00 CEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 09:00:00 CEST | Press release

Positive CHMP opinion is based on data from the Phase 3 RISE-PD trial, which demonstrated significantly more “Good ON” time with fewer daily doses compared with immediate-release levodopa/carbidopa More than one million people are living with Parkinson’s disease in the European Union, and over 80% experience motor fluctuations during the course of their disease, highlighting the need for additional treatment options Hopledo® contains a unique formulation combining immediate-release granules and extended-release pellets, providing both a rapid onset of action and a longer duration of effect, sustaining the levodopa therapeutic effect for a longer period of time If approved, Zambon expects to make Hopledo® progressively available to patients with Parkinson’s disease across Europe starting October 2026 Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European M

Enhertu® Approved in the EU as First Tumor Agnostic HER2 Directed Therapy and Antibody Drug Conjugate for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors29.6.2026 08:30:00 CEST | Press release

Approval based on three phase 2 trials of Daiichi Sankyo and AstraZeneca’s Enhertu that demonstrated clinically meaningful responses across a broad range of tumors Enhertu now approved for six indications in the EU Enhertu® (trastuzumab deruxtecan) has been approved in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from subgroups of patients with HER2 positive (IHC 3+) tumors across thr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye